TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prepubertal age~* Prepubertal characteristics~* Non GH deficient~* Short children (height \< -2.5 SDS)~* Born SGA (birth height \< -2 SDS)~* Parental height adjusted (\< -1 DS)~* No rhGH treatment before inclusion~Exclusion Criteria:~* ALLERY to rhGH or excipients~* Small height etiologies~* Cancer or cancer treatment ongoing~* Drugs interference with growth~* Mental impairment~* Hypertrophic cardiopathy impairment~* Hypertension not under controlled~* Intra cranial hypertension not controlled~* Diabetes and hyperglycaemia without diabetes~* Dyslipidemia~* Hepatitis~* Kidney failure~* Chromosomic aberration and/or genetic disorders (except Silver Russel Syndrome)~* No social security~* State of health in worst conditions after cardiac surgery, polytraumatism

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): the recommended dose in the EU of rhGH (Norditropine SimpleXx®)
- 2 (Type: ACTIVE_COMPARATOR): the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-Discharge Pharmacist-led Rapid Medication Optimization for Heart Failure (Post-Discharge PHARM-HF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥19 years;~2. Attending their initial visit to the PDMC;~3. Diagnosis of HF.~Exclusion Criteria:~* None.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pharmacist co-management (Type: EXPERIMENTAL): In addition to usual care, participants with an initial Post-Discharge Medicine Clinic visit randomized to the intervention arm will receive pharmacist co-management of their medications, with the intent of to achieve rapid, maximum-tolerated pharmacotherapy for HF as outlined in the latest guidelines. This intervention will be delivered by a staff pharmacist at the St. Paul's Hospital, using the standard procedures outlined below:~For HFrEF, where possible, a patient will be prescribed the combination of an ARNI, evidence-based beta-blocker, MRA, and SGLT2i at target HFrEF doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines.~For HFmrEF, we will target ACEI/ARB/ARNI, beta-blocker, MRA, and SGLT2i. For HFpEF, we will target SGLT2i + MRA +/- ACEI/ARB/ARNI. The intervention will incorporate key components identified in a systematic review of observational studies of pharmacist-led optimization of HF.
- Usual care (Type: OTHER): Usual care: Both the intervention group and comparator group will receive usual care by the Post-Discharge Medicine Clinic, which does not include clinical pharmacy services. The standard pathway in the St. Paul's Hospital Post-Discharge Medicine Clinic consists of an initial consultation with the clinic internist within 2 weeks of discharge, followed by two visits approximately 1 week apart with the Post-Discharge Medicine Clinic internist, followed by discharge from the clinic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 99mTc-MIBI SPECT/CT in Breast Malignancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically proven breast cancer~* Patients with locally advanced breast cancer (stages T2-4 N0-3 M0)~* Patients scheduled for neoadjuvant chemotherapy~* Patients scheduled for radical modified mastectomy~* Patients with no physical and/or psychological contraindications~* Patients with no recent nuclear medicine study using long-lived isotopes (i.e. 67Ga, 111In, 131I) within the 48 hour preceding the mammoscintigraphy~Exclusion Criteria:~* Patient with no histologically proven breast cancer~* Patients with early stage T1 breast cancer~* Patients who are not candidates for neoadjuvant chemotherapy~* Patients who are not surgical candidates~* Patients with physical and/or psychological contraindications~* Pregnant or breast feeding patients~* Patients with a recent nuclear medicine study using long-lived isotopes (i.e. 67Ga, 111In, 131I) within the 48 hour preceding the mammoscintigraphy

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Mammoscintigraphy with SPECT-CT optimized 99mTc-MIBI imaging (experimental arm) will be compared to conventional planar imaging. Mammoscintigraphy results before and after chemotherapy and radiation therapy, will be compared to the histopathological results after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with idiopathic epiretinal membrane~* Preoperative visual acuity of snellen equivalent 20/32 or worse~Exclusion Criteria:~* History or presence of any of the following:~* uveitis~* macular hole~* previous vitreoretinal surgery~* any other retinal pathology that could affect anatomic or functional results~* Age Related Macular Degeneration~* Diabetic Retinopathy~* Diabetic Macular Edema~* Retinal Vein Occlusion~* Pre-existing Macular Disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PPV + MP + DEX (Type: EXPERIMENTAL): Patients will undergo pars plana vitrectomy, membrane peel, and concomitant Ozurdex implant (0.7 mg dose).
- PPV + MP (Type: ACTIVE_COMPARATOR): Patients will undergo pars plana vitrectomy with membrane peel, without Ozurdex implant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males 18 years or older~* Severe hemophilia A (F.VIII \< 0.01 U/ml)~* At least 150 exposure days to F.VIII products~* No detectable inhibitor~* No history of allergic reaction~* Platelets at least 150,000/ul~* If HIV(+), CD4 at least 200/ul, HIV-VL \<48 copies/ml,and cART compliant~* If HCV(+), no splenomegaly,varices,GI bleed,ascites,edema,encephalopathy~* Willingness to comply with cross-over design, randomization schema~* Willingness to keep a personal diary of bleeding frequency and factor use~* Willingness to make every 3 month visits, coagulation testing at wks 2, 28~Exclusion Criteria:~* Acquired hemophilia~* Any bleeding disorder other than hemophilia A~* Presence of an inhibitor to factor VIII~* Historic platelet count \< 100,000~* Use of experimental drugs~* Surgery anticipate in the next 52 weeks~* Symptomatic HCV(splenomegaly,varices,GI bleed,ascites,edema,encephalopathy)~* Symptomatic HIV(CD4\<200/ul or HIV VL 48 or more copy/ml,cART noncompliant)~* Life expectancy less than 5 years~* Investigational drug or study within 4 weeks prior to study~* Inability to comply with study requirements

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): The intervention for Arm A is 40 IU/kg recombinant factor VIII (rFVIII) by once-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given thrice-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds.
- Arm B (Type: EXPERIMENTAL): The intervention for Arm B is 40 IU/kg recombinant factor VIII (rFVIII) by thrice-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given once-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3127804 in Participants With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are hospitalized with pneumonia, and presumed or confirmed COVID-19~* Are able and willing to give signed informed consent (legally authorized representative can provide informed consent if needed)~Exclusion Criteria:~* Female participants must not be pregnant and/or lactating~* Have Acute Respiratory Distress Syndrome (ARDS) or will require immediate intermittent mandatory ventilation (IMV), or are ineligible for IMV~* Have any concurrent serious medical condition (for example dialysis) or concomitant medication that would preclude participation in the study~* Are moribund irrespective of the provision of treatments~* Have a known history or show evidence of human immunodeficiency virus (HIV) and/or hepatitis~* Have recently undergone major surgery or central venous access device placement~* Have a significant bleeding disorder or active vasculitis~* Have experienced a thromboembolic event~* Have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia~* Have a serious, nonhealing wound, peptic ulcer, or bone fracture~* Have liver cirrhosis~* Have a known sensitivity to monoclonal antibodies (mAbs) or other therapeutic proteins~* Have a history of hypertensive crisis or hypertensive encephalopathy or current, poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3127804 (Type: EXPERIMENTAL): Participants received 20 milligrams (mg) per kilogram (kg) of LY3127804 as an intravenous (IV) infusion on Days 1 and 15.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received 20 mg/kg of Placebo as an IV infusion on Days 1 and 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Rehabilitation, Quality of Life, and Exercise Tolerance in Patients With an ICD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* First ICD implant within past 12 weeks~* Agrees to sign patient/partner informed consent~Exclusion Criteria:~* Angina pectoris CCS III \& IV~* NYHA functional class IV~* Inability to follow rehabilitation programme~* Exercise limitations due to clinical condition~* Symptomatic exercise-induced tachyarrhythmias~* Any major non-cardiac condition that would adversely affect survival during study duration~* Unable to comply to study procedures~* Participates in a concurrent study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Frailty in Elderly Patients With Advanced Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of advanced carcinoma - not suitable for curative treatment~* Age 70 years or over~* seen by an oncologist for consideration of palliative systemic medical therapy and decision regarding management already made~* WHO Performance Status 0-2~* Written informed consent~Exclusion Criteria:~* Hepatocellular cancer~* Prostate cancer~* Breast cancer

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age \> 18 years~* B-ALL in relapse~* refractory B-ALL-performance status of 0-2 on the Eastern Cooperative Oncology Group scale~* adequate hepatic and renal functions (AST or ALT \<= 5 times the upper limit of normal creatinine \< 2 times the upper limit of normal)~* \> 20% blasts in bone marrow,~* \> 30% of bone marrow blast population HER2 positive as assessed by immunophenotyping~Exclusion Criteria:~* Previous treatment by trastuzumab~* FEVG \< 50%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Image Guided Therapy in the Treatment of Gliomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, newly diagnosed intracranial glioma~* A diagnostic contrast enhanced CT/MRI demonstrating the lesion prior to registration~* Karnofsky performance status \>= 60~* Ability to undergo MR imaging with the use of Gadolinium dye~* Patient must sign a study specific informed consent form; if the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the patient's legal representative~Exclusion Criteria:~* Inability to obtain histological proof of glioma~* Allergy to Gadolinium contrast~* Any condition including metallic implants or cardiac pace makers that make the candidate ineligible for MR imaging~* Any medical condition including renal or cardiac insufficiency that make the candidate a high risk for gadolinium contrast administration~* Karnofsky performance status of =\< 50~* Prior history of radiation therapy to the brain~* Pregnancy

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients undergo magnetic resonance spectroscopic imaging, functional magnetic resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5 days a week for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants: 12 to \< 18 years old (Cohort 1), 6 to \< 12 years old (Cohort 2), 2 to \< 6 years old (Cohort 3), Weighing \> 8 kg to \< 2 years old (Cohort 4), and 28 days old to weighing ≤ 8 kg (Cohort 5).~* Undergone 1 allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor and source for hematological malignancies or disorders. Recipients of myeloablative and reduced-intensity conditioning regimens are eligible.~* Clinically suspected Grade II to IV aGVHD as per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria, occurring after allo-HSCT and any GVHD prophylactic medication.~* Evidence of myeloid engraftment.~Exclusion Criteria:~* More than 1 allo-HSCT.~* Received more than 2 days of systemic corticosteroids for aGVHD before the first study drug administration.~* Presence of GVHD overlap syndrome.~* Presence of an active uncontrolled infection.~* Known HIV infection.~* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment or at risk for HBV reactivation.~* Evidence of relapsed primary disease or have been treated for relapse after the allo-HSCT was performed.~* Any corticosteroid therapy for indications other than GVHD at doses \> 1 mg/kg once daily of methylprednisolone (or equivalent) within 7 days of the first study drug administration.~* Receipt of live (including attenuated) vaccines or anticipation of need for such vaccines during the study.~* Receipt of JAK inhibitor therapy after allo-HSCT for any indication.~* Treatment with any other investigational agent, device, or procedure within 21 days (or 5 half-lives, whichever is greater) of enrollment.

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Itacitinib + Corticosteroids (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Losartan to Improve Hip Microfracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Underwent primary hip arthroscopy~* Underwent baseline quantitative MRI at The Steadman Clinic (TSC)~* Single, localized, grade 3 or 4 cartilage lesion of the acetabulum or femoral head treated with Bone Marrow Stimulation (BMS; i.e. microfracture)~* Aged 18-60 at time of surgery~* Tonnis grade 1 or less~Exclusion Criteria:~* Two or more cartilage lesions of grade 3 or 4~* Less than 2 mm of minimal hip joint space~* Osteoarthritis or diffuse change of cartilage~* Non-English speaking~* Prior hip surgery on operative hip~* Pre-existing bony deformity caused by previous fracture(s)~* Synovial chondromatosis~* Pigmented Villonodular Synovitis (PVNS)~* Dysplasia (center edge angle \<20 degrees)~* History of Avascular Necrosis (AVN), Perthes disease, or slipped capital femoral epiphysis (SCFE)~* Inflammatory arthritis or other arthritis caused by autoimmune disease~* Patients allergic to any active or inactive ingredient of losartan~* Patients taking medication with known losartan interaction, including phenobarbital, rifampin, and fluconazole.~* Subjects that are currently taking losartan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Losartan (Type: EXPERIMENTAL): 12.5mg Losartan capsules, oral administration, twice daily (25mg total per day), taken for 30 consecutive days starting on the evening of the second post-surgery day.
- Placebo (Type: PLACEBO_COMPARATOR): Appearance-matched placebo capsules, oral administration, twice daily, taken for 30 consecutive days starting on the evening of the second post-surgery day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study.~* Age \> 18 years~* Adult, non-gravid patients with malignancy and symptomatic loculated pleural effusion who has undergone percutaneous drainage will be eligible to participate. A loculated effusion is defined as an effusion whose contents cannot be completely drained at the time of initial catheter placement as documented by the initial imaging guided procedure or within 48 hours of catheter placement by chest radiography. Malignant cells need not be found within the pleural fluid.~Exclusion Criteria:~* Active internal bleeding, involving intracranial and retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts~* History of stroke within 3 months~* Intracranial neoplasm, arteriovenous malformation, or aneurysm.~* Uncorrectable bleeding diathesis (INR \> 1.5 despite therapy)~* Recent intracranial or intraspinal surgery or trauma~* Pregnancy (positive pregnancy test)~* Severe uncontrolled hypertension~* Documented empyema~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Participation in another simultaneous medical investigation or trial~* Participation in another clinical investigation within previous 30 days of catheter placement~* Prior enrollment in the study~* Known allergy to TNK or any of its components

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: PLACEBO_COMPARATOR): Loculated pleural effusion infused with normal saline twice a day for three days.
- TNKase (Type: ACTIVE_COMPARATOR): Loculated pleural effusion infused with TNK twice a day for three days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues